Article Versions Notes

Sehouli J, Mustea A, Oskay-Özcelik G, Keller M, Richter R, Tomé O, Woopen H, Sommer-Joos A-K, Grabowski JP, Armbrust R, et al. Bevacizumab Combined with Platinum–Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients. Cancers. 2021; 13(19):4739. https://doi.org/10.3390/cancers13194739

Sehouli, Jalid, Alexander Mustea, Guelten Oskay-Özcelik, Maren Keller, Rolf Richter, Oliver Tomé, Hannah Woopen, Ann-Katrin Sommer-Joos, Jacek P. Grabowski, Robert Armbrust, and et al. 2021. "Bevacizumab Combined with Platinum–Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients" Cancers 13, no. 19: 4739. https://doi.org/10.3390/cancers13194739

Sehouli, J., Mustea, A., Oskay-Özcelik, G., Keller, M., Richter, R., Tomé, O., Woopen, H., Sommer-Joos, A.-K., Grabowski, J. P., Armbrust, R., & Wimberger, P., on behalf of the North-Eastern German Society of Gynaecological Oncology (NOGGO). (2021). Bevacizumab Combined with Platinum–Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients. Cancers, 13(19), 4739. https://doi.org/10.3390/cancers13194739